Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

NCT07787182 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07787182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07787182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
January 31, 2028
Enrollment
68 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, amyloid, healthy volunteers, plaque, amyloid